In vitro receptor binding assays: General methods and considerations

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 3, 2008, Pages 245-253

  Bigott Hennkens, H M ^a   Dannoon, S ^a   Lewis, M R ^a,b,c   Jurisson, S ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Radioligand assay; Radiopharmaceuticals; Receptors cell surface

Indexed keywords

CELL SURFACE RECEPTOR; RADIOPHARMACEUTICAL AGENT;

BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; CALCULATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; IC 50; IN VITRO STUDY; INTERNALIZATION; LIGAND BINDING; REVIEW;

BINDING, COMPETITIVE; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; INHIBITORY CONCENTRATION 50; KINETICS; LIGANDS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; RADIOISOTOPES; RADIOPHARMACEUTICALS; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 48749132016     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Mansi R, Tesauro D, De Capua A, Fattorusso R, Caraco C, Aloj L et al. Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: synthesis and characterization. Biopolymers 2004;76:527-34.
2. 99mTc-depreotide. Eur J Nucl Med Mol Imaging 2004;31:1022-30.
3. Ginj M, Hinni K, Tschumi S, Schulz S, Maecke HR. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med 2005;46:2097-103.
4. Parry JJ, Eiblmaier M, Andrews R, Meyer LA, Higashikubo R, Anderson CJ et al. Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells. Mol Imag 2007;6:56-67.
5. Motulsky HJ, Christopoulos A. fitting models to biological data using linear and nonlinear regression: a practical guide to curve fitting. San Diego: GraphPad Software, Inc.; 2003.
6. Goldstein A, Barrett RW. Ligand dissociation constants from competition binding assays: errors associated with ligand depletion. Mol Pharmacol 1987;31:603-9.
7. 3-octreotate us-g a cross-bridged macrocyclic chelator. Clin Cancer Res 2004;10:8674-82.
8. Anderson CJ, Jones LA, Bass LA, Sherman ELC, McCarthy DW, Cutler PD et al. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med 1998;39:1944-51.
9. Cyr JE, Pearson DA, Wilson DM, Nelson CA, Guaraldi M, Azure MT et al. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. J Med Chem 2007;50:1354-64.
10. Fisher WE, Wu Y, Amaya F, Berger DH. Somatostatin receptor subtype 2 gene therapy inhibits pancreatic cancer in vitro. J Surg Res 2002;105:58-64.
11. Ginj M, Schmitt JS, Chen J, Waser B, Reubi JC, de Jong M et al. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol 2006;13:1081-90.
12. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82.
13. Fridkin G, Bonasera TA, Litman P, Gilon C. Backbone metalcyclization: a novel approach for simultaneous peptide cyclization and radiolabeling. Application to the combinatorial synthesis of rhenium-cyclic somatostatin analogs. Nucl Med Biol 2005;32:39-50.
14. Raynor K, Reisine T. Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain. J Pharmacol Exp Ther 1989;251:510-7.
15. 50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-108.
16. 3)-octreotate derivatives for longer intracellular probe residence. Bioconjugate Chem 2004;15:647-57.
17. 8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors. Nucl Med Biol 2007; 34:651-7.
18. Wild D, Schmitt JS, Ginj M, Maecke HR, Bernard BE, Krenning E et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-47.